A newly published review article brings fresh attention to ACSL4, a key enzyme increasingly recognized for its central role in the progression of Alzheimer’s disease. By connecting multiple biological processes, the findings position ACSL4 as a compelling focal point for future therapeutic innovation and a potential driver of disease mechanisms.

Alternative splicing is a process by which a single gene is edited to produce multiple different versions, thereby increasing the size of the functional genome.

In a new Molecular Cell study, researchers discovered that nitric oxide—a gas produced in the body—broadly regulates alternative splicing, dramatically altering gene function.

The team also found that nitric oxide levels are reduced in the brains of patients with Alzheimer’s disease, and that this loss of regulation over gene splicing correlates with worse clinical outcomes.

Historically, researchers believed nitric oxide levels in Alzheimer’s brains were too high and contributed to disease development. This study challenges that long-standing view.

For the first time, therapeutically effective medications are now available for Alzheimer’s disease. Effective symptomatic therapies also exist for Parkinson’s disease. However, a prerequisite for successful treatment is early diagnosis – ideally through a simple blood test conducted as part of a preventive screening, even before clinical symptoms appear. A research team led by Professor Klaus Gerwert from Ruhr University Bochum, Germany, has developed just such a blood test. It is based on the immuno-infrared sensor, a novel platform technology to which the Journal of Physical Chemistry B dedicates its cover story in its issue from April 24, 2026.